CPG & GZK-111ЦПГ / ГЗК-111
Cycloprolylglycine (CPG) is a naturally occurring cyclic dipeptide formed from proline and glycine. GZK-111 is an experimental linear precursor. CPG has also been measured as a metabolite of Noopept.
What the studies found
Animal research · 2018
Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats
Findings for this preparation
After Noopept administration in rats, researchers detected its metabolite cycloprolylglycine in plasma and brain. Its pharmacokinetic profile differed from that of Noopept. This experiment measured CPG after exposure to the parent compound.
Study notes · methods, sources and limitations
Participants or model Rat plasma and brain pharmacokinetic study.
Important limitations
- Animal metabolite kinetics do not establish human exposure, cognitive benefit or a dosing interval.
Biomeditsinskaya Khimiya. 2018;64(5):455–458. · Journal publication
Biomarker study in people · no treatment tested · 2019
Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.
Naturally occurring CPG measured in blood; no CPG treatment given
- Biomarker association
- Lower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its changeNo correlation coefficient or absolute concentration in the indexed abstract
In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.
Study notes · methods, sources and limitations
Participants or model 34 stroke patients recruited within three days; 50 age-matched controls
Design 34 patients recruited within 3 days of stroke; 50 age-matched controls without stroke.
- Participants
- 34 stroke patients; 50 controls
- Assessment schedule
- Baseline within 3 days; days 7 and 90
Important limitations
- Observational association is not evidence that CPG administration improves stroke recovery. Small cohort; causal interpretation and external predictive validity remain unresolved. Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
- An association with endogenous cGP does not show that giving cGP or GZK-111 improves recovery.
Annals of clinical and translational neurology (2019); PMID 31019991 · Indexed abstract
Animal research · 2022
Metabolism of a New Dipeptide Neuroprotector in Rats.
Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.
Study notes · methods, sources and limitations
Participants or model Rat plasma HPLC–mass spectrometry
Important limitations
- Metabolite identification does not establish human pharmacokinetics, brain exposure or clinical equivalence to Noopept. Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Bulletin of experimental biology and medicine (2022); PMID 35352249 · Indexed abstract
About CPG & GZK-111
Names in this research collection
CPG · CGP · Cycloprolylglycine · cyclo(Pro-Gly) · cyclo(Gly-Pro) · GZK-111 · pGlu-Asn-NH2
Research background
A grouped record for endogenous cyclo(Pro-Gly), its experimental linear precursor GZK-111 and the connection to Noopept metabolism.
- Compound class
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No human treatment trial assessed for this family
Study methods
Member-specific studies; patents and archival leads identified separately
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Cell and animal effects do not establish human safety; analogues may differ
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2018
GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
Study notes and original source
GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Сергей Борисович Середенин, Татьяна Александровна Гудашева, Ксения Николаевна Колясникова, Елена Александровна Кузнецова, Татьяна Александровна Воронина, Милада Альнордовна Яркова, Татьяна Алексеевна Антипова, Светлана Александровна Литвинова, Николай Николаевич Золотов · RU2646604C2 · patent family 59497169
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
Results and tables
Reported patent results
Findings described in words
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
Population or model GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Metabolic identity | CPG formation observed during incubation with plasma and brain homogenate | Supports a precursor/metabolite relationship; not a human clinical exposure estimate |
| Cell-injury comparison | Concentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell model | No quantitative cell-survival percentage independently transcribed |
| Animal findings | Increased survival time under experimental hypoxia and anxiolytic-like behavioral findings reported at selected exposures | Different compounds and assays must not be pooled |
These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
- These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · 2018
Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats
After Noopept administration in rats, researchers detected its metabolite cycloprolylglycine in plasma and brain. Its pharmacokinetic profile differed from that of Noopept. This experiment measured CPG after exposure to the parent compound.
Study notes and original source
Pharmacokinetics of Noopept and its active metabolite cycloprolylglycine in rats
· Journal publication
S. S. Boyko, V. P. Zherdev, R. V. Shevchenko · Biomeditsinskaya Khimiya. 2018;64(5):455–458.
Cycloprolylglycine was found in rat plasma and brain and had a pharmacokinetic profile different from the parent drug. The paper relates these findings to memory-associated pharmacology.
- Population / setting
- Rat plasma and brain pharmacokinetic study.
- Source reviewed
- Primary PubMed abstract and bibliographic metadata checked; full concentration-time tables not reviewed.
Study limitations
- Animal metabolite kinetics do not establish human exposure, cognitive benefit or a dosing interval.
Reviewed 2026-11-01.
Animal research · 2022
Metabolism of a New Dipeptide Neuroprotector in Rats.
Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.
Study notes and original source
Metabolism of a New Dipeptide Neuroprotector in Rats.
Kolyvanov GB, Bochkov PO, Litvin AA, Shevchenko RV, Podol'ko AL, Kravtsova OY, Kolyasnikova KN, Zherdev VP · Bulletin of experimental biology and medicine (2022); PMID 35352249
Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.
- Population / setting
- Rat plasma HPLC–mass spectrometry
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- Metabolite identification does not establish human pharmacokinetics, brain exposure or clinical equivalence to Noopept.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-10-17.
Biomarker study in people · no treatment tested · 2019
Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.
In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.
Biomarker association · Lower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its change · No correlation coefficient or absolute concentration in the indexed abstract
Study notes and original source
Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients.
Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J · Annals of clinical and translational neurology (2019); PMID 31019991
In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.
Results and tables
Reported findings and study design
In 34 stroke patients, baseline cyclic glycine-proline/IGF-1 ratio was associated with later neurological recovery. Patients were not treated with cGP; this was a biomarker study.
34 patients recruited within 3 days of stroke; 50 age-matched controls without stroke.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Biomarker association | Lower baseline cGP and cGP/IGF-1 ratio in stroke; baseline ratio correlated with day-90 NIHSS and its change | No correlation coefficient or absolute concentration in the indexed abstract |
| Participants | 34 stroke patients; 50 controls | |
| Assessment schedule | Baseline within 3 days; days 7 and 90 |
An association with endogenous cGP does not show that giving cGP or GZK-111 improves recovery.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 34 stroke patients recruited within three days; 50 age-matched controls
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- Observational association is not evidence that CPG administration improves stroke recovery. Small cohort; causal interpretation and external predictive validity remain unresolved.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-11-01.
Animal research · 2014
Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.
The investigators reported context-dependent modulation of IGF-1 activity and modeled altered binding to IGFBP-3. Animal experiments reported improved ischemic recovery and inhibited lymphoma growth.
Study notes and original source
Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.
Guan J, Gluckman P, Yang P, Krissansen G, Sun X, Zhou Y, Wen J, Phillips G, Shorten PR, McMahon CD, Wake GC, Chan WH, Thomas MF, Ren A, Moon S, Liu DX · Scientific reports (2014); PMID 24633053
The investigators reported context-dependent modulation of IGF-1 activity and modeled altered binding to IGFBP-3. Animal experiments reported improved ischemic recovery and inhibited lymphoma growth.
- Population / setting
- Cell culture, mathematical modeling, rat ischemic brain injury and mouse tumor experiments
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- Multiple experimental systems do not establish a clinical mechanism or treatment benefit. The IGF-1 measurements and the Russian AMPA/TrkB experiments address different pathways.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-10-17.
Animal research · 2002
[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].
GVS-111 altered coagulation and fibrinolysis in experimental work. In-vitro CPG also showed antiaggregant activity; concentrations extending to 10⁻¹⁰ M were reported.
Study notes and original source
[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].
Ostrovskaia RU, Liapina LA, Pastorova VE, Mirzoev TKh, Gudasheva TA, Seredenin SB, Ashmarin IP · Eksperimental'naia i klinicheskaia farmakologiia (2002); PMID 12109290
GVS-111 altered coagulation and fibrinolysis in experimental work. In-vitro CPG also showed antiaggregant activity; concentrations extending to 10⁻¹⁰ M were reported.
- Population / setting
- In-vivo GVS-111 experiments and in-vitro coagulation assays
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- The in-vivo regimen was for GVS-111, not CPG. Laboratory coagulation findings do not establish stroke prevention, bleeding safety or a human dose.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-10-17.
Review of earlier studies · 2023
Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions.
The review brings together cGP/IGF-1 associations and experimental intervention studies. Its stroke biomarker discussion includes the separately listed 2019 cohort.
Study notes and original source
Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions.
Guan J, Li F, Kang D, Anderson T, Pitcher T, Dalrymple-Alford J, Shorten P, Singh-Mallah G · Molecules (Basel, Switzerland) (2023); PMID 36770687
The review brings together cGP/IGF-1 associations and experimental intervention studies. Its stroke biomarker discussion includes the separately listed 2019 cohort.
- Population / setting
- Narrative review of experimental and clinical biomarker research
- Source reviewed
- Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Study limitations
- Review synthesis is not an independent trial. The human studies report associations. The treatment experiments were in animals.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Reviewed 2026-10-17.
Review of earlier studies · 2025
Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action
The authors discuss two proposed mechanisms: IGF-1 homeostasis and AMPA modulation with downstream neurotrophin signaling. The review connects the endogenous peptide with the Noopept research lineage.
Study notes and original source
Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action
T. A. Gudasheva, K. N. Koliasnikova, A. G. Alyaeva, P. Yu. Povarnina · Neurochemical Journal 19:549–556 (2025); published online 13 January 2026
The authors discuss two proposed mechanisms: IGF-1 homeostasis and AMPA modulation with downstream neurotrophin signaling. The review connects the endogenous peptide with the Noopept research lineage.
- Population / setting
- Narrative synthesis of CPG research
- Source reviewed
- Primary publisher abstract, publication dates and references checked.
Study limitations
- A synthesis of earlier studies, not a new efficacy trial or independent replication.
- Publisher abstract and references checked; subscription full text not reviewed.
Reviewed 2026-10-17.
Animal research · 2022
Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.
GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
Study notes and original source
Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.
Litvin AA, Kolyvanov GB, Bochkov PO, Shevchenko RV, Podol'ko AL, Kolyasnikova KN, Zherdev VP · Bulletin of experimental biology and medicine
GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
- Population / setting
- Rats; intravenous and intragastric pharmacokinetics
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Laboratory analysis · 1996
Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain.
Chromatographic and mass-spectrometric methods identified CPG in rat brain. Synthetic CPG also altered passive-avoidance performance in rats. Endogenous detection does not establish supplementation benefit.
Endogenous brain CPG content · 2.8 ± 0.3 nmol/g wet brain
Study notes and original source
Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain.
Gudasheva TA, Boyko SS, Akparov VKh, Ostrovskaya RU, Skoldinov SP, Rozantsev GG, Voronina TA, Zherdev VP, Seredenin SB · FEBS letters
Chromatographic and mass-spectrometric methods identified CPG in rat brain. Synthetic CPG also altered passive-avoidance performance in rats. Endogenous detection does not establish supplementation benefit.
Results and tables
Reported findings and study design
Endogenous CPG detection in rat brain plus a rat passive-avoidance assay using synthetic CPG 0.1 mg/kg IP.
Population or model Rat brain extracts and rat behavioral experiments
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Endogenous brain CPG content | 2.8 ± 0.3 nmol/g wet brain | |
| Antiamnesic response | Reported at 0.1 mg/kg | No numerical behavioral effect size supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rat brain extracts and rat behavioral experiments
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 1997
The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.
Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.
Study notes and original source
The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.
Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB · European journal of drug metabolism and pharmacokinetics
Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.
- Population / setting
- Rat metabolism and enzyme preparations
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Lab research · 2016
Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.
CPG enhanced AMPA currents in rat cerebellar Purkinje cells. A proposed downstream BDNF mechanism requires distinction from the measured electrophysiological response.
Study notes and original source
Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.
Gudasheva TA, Grigoriev VV, Koliasnikova KN, Zamoyski VL, Seredenin SB · Doklady. Biochemistry and biophysics
CPG enhanced AMPA currents in rat cerebellar Purkinje cells. A proposed downstream BDNF mechanism requires distinction from the measured electrophysiological response.
- Population / setting
- Rat Purkinje-cell electrophysiology
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Lab research · 2022
Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.
AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.
Study notes and original source
Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.
Gudasheva TA, Koliasnikova KN, Alyaeva AG, Nikolaev SV, Antipova TA, Seredenin SB · Doklady. Biochemistry and biophysics
AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.
- Population / setting
- Cultured-cell injury and receptor-blockade experiments
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 2016
Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.
CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.
Study notes and original source
Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.
Povarnina PY, Kolyasnikova KN, Nikolaev SV, Antipova TA, Gudasheva TA · Bulletin of experimental biology and medicine
CPG improved selected neurological and locomotor measures after incomplete global ischemia in rats and protected HT-22 cells against glutamate toxicity.
- Population / setting
- Rat ischemia model and HT-22 cells
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Lab research · 2004
Pyroglutamyl-asparagine amide normalizes long-term potentiation in rat hippocampal slices.
Pyroglutamyl-asparagine amide facilitated weakly induced long-term potentiation and countered ethanol-impaired potentiation in rat hippocampal slices. This separate piracetam-inspired dipeptide is not CPG.
Study notes and original source
Pyroglutamyl-asparagine amide normalizes long-term potentiation in rat hippocampal slices.
Kapai NA, Chepkova AN, Gudasheva TA, Morozova AA, Skrebitskii VG · Bulletin of experimental biology and medicine
Pyroglutamyl-asparagine amide facilitated weakly induced long-term potentiation and countered ethanol-impaired potentiation in rat hippocampal slices. This separate piracetam-inspired dipeptide is not CPG.
- Population / setting
- Rat hippocampal slices
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Review of earlier studies · 2018
Novel Technologies for Dipeptide Drugs Design and their Implantation.
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Study notes and original source
Novel Technologies for Dipeptide Drugs Design and their Implantation.
Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
- Population / setting
- Developer account of medicinal-chemistry programs
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Developer review; claims require appraisal of each original study.
- A shared design method does not establish equivalent biology or clinical benefit.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗